A comparison of different methods for the first-in-pediatric dose selection
Background and aim: In order to conduct a pediatric clinical trial, it is important to optimize pediatric dose as accurately as possible. This is mainly because due to ethical reasons, children cannot be given several doses to evaluate pharmacokinetics, safety, and efficacy of a drug.
Methods: In this study, several simple methods to project a first-in-pediatric dose to initiate a clinical trial were evaluated. These methods were: 1. Weight-based pediatric dose prediction (allometric scaling), 2. Salisbury Rule (weight-based method), and 3. Pediatric dose prediction based on predicted clearance. These methods were compared with the dose given to children in clinical practice. The methods were also compared with whole body PBPK model (n =11). A ±30% prediction error (predicted vs observed) was considered acceptable.
Results: There were 27 drugs with 113 observations (different age groups from preterm neonates to adolescents). At least, ≤30% prediction error in pediatric dose projection was noted for more than 70% observations. The predictive performance of all the proposed methods were comparable with the whole body PBPK.
Conclusion: The proposed methods are simple and accurate and can be developed on a spreadsheet in a very short period of time.
Relevance for patients: The study provides an estimate of first-in-pediatric dose by simple methods to initiate pediatric clinical trials. Especially, Salisbury Rule which is based on body weight and is very simple and works fairly well in children >30 kg body weight and can be even used in clinical settings.
[1] Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental Pharmacology: Drug Disposition, Action, and Therapy in Infants and Children. N Engl J Med 2003;349:1157-67.
[2] Mahmood I. Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings. Clin Pharmacokinet 2014;53:327-46.
[3] Weiss CF, Glazko A, Weston JK. Chloramphenicol in the Newborn Infant. A Physiologic Explanation of its Toxicity when given in Excessive doses. N Engl J Med 1960;262:787-94.
[4] Silverman WA, Anderson DH, Blanc WA, Crozie DN. ADifference in Mortality Rate and Incidence of Kernicterus among Premature Infants Allotted to Two Prophylactic Anti-Bacterial Regimens. Pediatrics 1956;18:614-25.
[5] Green DJ, Zineh I, Burckart GJ. Pediatric Drug Development: Outlook for Science-Based Innovation. Clin Pharmacol Ther 2018;103:376-8.
[6] Abernethy DR, Burckart GJ. Pediatric dose Selection. Clin Pharmacol Ther 2010;87:270-1.
[7] Elias GP, Antoniali C, Mariano RC. Comparative Study of Rules Employed for Calculation of Pediatric Drug Dosage. J Appl Oral Sci 2005;13:114-9.
[8] Mahmood I. Dose Selection in Children: Allometry and Other Methods. In: Pediatric Pharmacology and Pharmacokinetics. Rockville: Pine House Publishers; 2008. p. 184-216.
[9] Mahmood I. Dose Selection in Children. In: Pharmacokinetic Allometric Scaling in Pediatric Drug Development. Rockville: Pine House Publishers; 2013. p. 151-60.
[10] Lack JA, Stuart-Taylor ME. Calculation of Drug Dosage and Body Surface Area of Children. Br J Anaesth 1997;78:601-5.
[11] Kee JL, Marshall SM. Calculations for Specialty Areas. In: Clinical Calculations: With Applications to General and Specialty Areas. 7th ed. St Louis: Elseviers (Saunders); 2012. p. 240-69.
[12] Munzenberger PJ, McKercher P. Pediatric Dosing the Pharmacist’s Dilemma. Contemp Pharm Pract 1980;3:11-4.
[13] Jacobs RF, Maples HD, Aranda JV, Espinoza GM, Knirsch C, Chandra R, et al. Pharmacokinetics of Intravenously Administered Azithromycin in Pediatric Patients. Pediatr Infect Dis J 2005;24:34-9.
[14] Garey KW, Amsden GW. Intravenous Azithromycin. Ann Pharmacother 1999;33:218-28.
[15] Food and Drug Administration. FDA Package Insert of Azithromycin (Zithromax). Silver Spring: Food and Drug Administration; 2013.
[16] Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of Azithromycin in Pediatric Patients after Oral Administration of Multiple doses of Suspension. Antimicrob Agents Chemother 1993;37:314-6.
[17] Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of Azithromycin in Pediatric Patients with Acute Otitis Media. Antimicrob Agents Chemother 1995;39:1875-7.
[18] Jungbluth GL, Welshman IR, Hopkins NK. Linezolid Pharmacokinetics in Pediatric Patients: An Overview. Pediatr Infect Dis J 2003;22:S153-7.
[19] Food and Drug Administration. FDA Package Insert of Linezolid (Zyvox). Silver Spring: Food and Drug Administration; 2010.
[20] Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of Anti-Influenza Prodrug Oseltamivir in Children Aged 1-5 Years. Eur J Clin Pharmacol 2003;59:411-5.
[21] Food and Drug Administration. FDA Package Insert of Oseltamivir (Tamiflu). Silver Spring: Food and Drug Administration; 2012.
[22] Wenning LA, Murphy MG, James LP, Blumer JL, Marshall JD, Baier J, et al. Pharmacokinetics of Famotidine in Infants. Clin Pharmacokinet 2005;44:395-406.
[23] James LP, Marshall JD, Heulitt MJ, Wells TG, Letzig L, Kearns GL. Pharmacokinetics and Pharmacodynamics of Famotidine in Children. J Clin Pharmacol 1996;36:48-54.
[24] Nagita A, Manago M, Aoki S, Mino M, Suzuki K, Ashida K. Pharmacokinetics and Pharmacodynamics of Famotidine in Children with Gastroduodenal Ulcers. Ther Drug Monit 1994;16:444-9.
[25] Food and Drug Administration. FDA Package Insert of Famotidine (Pepcid). Silver Spring: Food and Drug Administration; 1986.
[26] Food and Drug Administration. FDA Package Insert of Fluconazole (Diflucan). Silver Spring: Food and Drug Administration; 2011.
[27] Zhou H, Herron J, Clyde C, Lee P, Mechlinski W, PescoKoplowitz L. Pharmacokinetic Profile of Cisapride 20 mg After Once-and Twice-Daily Dosing. Clin Ther 1998;20:292-8.
[28] Kearns GL, Robinson PK, Wilson JT, Wilson-Costello D, Knight GR, Ward RM, et al. Cisapride Disposition in Neonates and Infants: In Vivo Reflection of Cytochrome P450 3A4 Ontogeny. Clin Pharmacol Ther 2003;74:312-25.
[29] Blumer J, Batisky DL, Wells T, Shi V, Solar-Yohay S, Sunkara G. Pharmacokinetics of Valsartan in Pediatric and Adolescent Subjects with Hypertension. J Clin Pharmacol 2009;49:235-41.
[30] Food and Drug Administration. FDA Package Insert of Valsartan (Diovan (Valsartan)). Silver Spring: Food and Drug Administration; 1996.
[31] Killian A, Davis PJ, Stiller RL, Cicco R, Cook DR, Guthrie RD. Influence of Gestational age on the Pharmacokinetics of Alfentanil in Neonates. Dev Pharmacol Ther 1990;35:82-5.
[32] Meistelman C, Saint-Maurice C, Lepaul M, Loose JP, Levron JC. Pharmacokinetics of Alfentanil in Children. Anesthesiology 1984;61:A443.
[33] Den Hollander JM, Hennis PJ, Burm AG, Bovill JG. Alfentanil in Infants and Children with Congenital Heart Defects. J Cardiothorac Anesth 1988;2:12-7.
[34] Rautiainen P. Alfentanil Infusion for Sedation in Infants and Small Children during Cardiac Catheterization. Can J Anaesth 1991;38:980-4.
[35] Food and Drug Administration. FDA Package Insert of Alfentanil (Alfentanil HCL Injection). Silver Spring: Food and Drug Administration; 2016.
[36] Chien S, Well TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA, et al. Levofloxacin Pharmacokinetics in Children. J Clin Pharmacol 2005;45:153-60.
[37] Food and Drug Administration. FDA Package Insert of Levofloxacin (LEVAQUIN® (levofloxacin) Injection). Silver Spring: Food and Drug Administration; 2008.
[38] Franko TG, Powell DA, Nahata MC. Pharmacokinetics of Theophylline in Infants with Bronchiolitis. Eur J Clin Pharmacol 1982;23:123-7.
[39] El Desoky E, Ghazal MH, Mohamed MA, Klotz U. Disposition of Intravenous Theophylline in Asthmatic Children: Bayesian Approach vs Direct Pharmacokinetic Calculations. Jpn J Pharmacol 1997;75:13-20.
[40] Loughnan PM, Sitar DS, Ogilvie RI, Eisen A, Fox Z, Neims AH. Pharmacokinetic Analysis of the Disposition of Intravenous Theophylline in Young Children. J Pediatr 1976;88:874-9.
[41] Simons FE, Simons KJ. Pharmacokinetics of Theophylline in Infancy. J Clin Pharmacol 1978;18:472-6.
[42] Dothey CI, Tserng KY, Kaw S, King KC. Maturational Changes of Theophylline Pharmacokinetics in Preterm Infants. Clin Pharmacol Ther 1989;45:461-8.
[43] Giacoia G, Jusko WJ, Menke J, Koup JR. Theophylline Pharmacokinetics in Premature Infants with Apnea. J Pediatr 1976;89:829-32.
[44] Latini R, Assael BM, Bonati M, Caccamo ML, Gerna M, Mandelli M, et al. Kinetics and Efficacy of Theophylline in the Treatment of Apnea in the Premature Newborn. Eur J Clin Pharmacol 1978;13:203-7.
[45] Food and Drug Administration. FDA Package Insert of Theophylline. (Theophylline in Dextrose Theophylline Injection). Silver Spring: Food and Drug Administration; 2008.
[46] Battino D, Croci D, Rossini A, Messina S, Mamoli D, Perucca E. Topiramate Pharmacokinetics in Children and Adults with Epilepsy. A Case-Matched Comparison Based on Therapeutic Drug Monitoring Data. Clin Pharmacokinet 2005;44:407-16.
[47] Mikaeloff Y, Rey E, Soufflet C, d’Athis P, Echenne B, Vallée L, et al. Topiramate Pharmacokinetics in Children with Epilepsy Aged from 6 Months to 4 Years. Epilepsia 2004;45:1448-52.
[48] Food and Drug Administration. FDA Package Insert of Topiramate (TOPAMAX (Topiramate) TABLETS). Silver Spring: Food and Drug Administration; 2012.
[49] Khalil F, Choi SL, Watson E, Tzschentke TM, Lefeber C, Eerdekens M, et al. Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old. J Pain Res 2020;13:3107.
[50] European Medicine Agency. Summary of Product Characteristics (PALEXIA), Health Products Regulatory Authority. Amsterdam: European Medicine Agency; 2020.
[51] Rocha M, Almeida A, Afonso E, Martins V, Santos J, Leitao F, et al. The Kinetic Profile of Gentamicin in Premature Neonates. J Pharm Pharmacol 2000;52:1091-7.
[52] Walker JM, Wise R, Mitchard M. The Pharmacokinetics of Amikacin and Gentamicin in Volunteers: A Comparison of Individual Differences. J Antimicrobial Chemother 1979;5:95-9.
[53] Greeley WJ, de Bruijn NP, Davis DP. Sufentanil Pharmacokinetics in Pediatric Cardiovascular Patients. Anesth Analg 1987;66:1067-72.
[54] Food and Drug Administration. FDA Package Insert for Sufentanil Citrate Injection, USP CII. Silver Spring: Food and Drug Administration; 2014.
[55] Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of Vancomycin in Critically Ill Infants Undergoing Extracorporeal Membrane Oxygenation. Antimicrob Agents Chemother 1996;40:1139-42.
[56] Jarrett RV, Marinkovich GA, Gayle EL, Bass JW. Individualized Pharmacokinetic Profiles to Compute Vancomycin Dosage and Dosing Interval in Preterm Infants. Pediatr Infect Dis J 1993;12:156-7.
[57] Food and Drug Administration. FDA Package Insert for Vancomycin. Silver Spring: Food and Drug Administration; 2017.
[58] Van Den Anker JN, John N, Van Der Heijden, Bert J, Hop WC, Schoemaker RC, et al. The Effect of Asphyxiaon the Pharmacokinetics of Ceftazidime in the Term Newborn. Pediatr Res 1995;38:808-11.
[59] Van Den Anker JN, Hop WC, Schoemaker RC, Heijden VD, Neijens HJ, Groot R. Ceftazidime Pharmacokinetics in Preterm Infants: Effect of Postnatal age and Postnatal Exposure to Indomethacin. Br J Clin Pharmacol 1995;40:439-43.
[60] Food and Drug Administration. FDA Package Insert of Ceftadizime (FORTAZ). Silver Spring: Food and Drug Administration; 2007.
[61] Stass H, Lettieri J, Vanevski KM, Willmann S, James LP, Sullivan JE, et al. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. J Clin Pharmacol 2019;59:654-67.
[62] Willmann S, Frei M, Sutter G, Coboeken K, Wendl T, Eissing T, et al. Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation during the Pediatric Development of Moxifloxacin. CPT Pharmacometrics Syst Pharmacol 2019;8:654-63.
[63] Food and Drug Administration. FDA Package Insert of Moxifloxacin (AVELOX). Silver Spring: Food and Drug Administration; 2016.
[64] Johnson TN, Cleary Y, Parrott N, Reigner B, Smith JR, Toovey S. Development of a Physiologically Based Pharmacokinetic Model for Mefloquine and its Application alongside a Clinical Effectiveness Model to Select an Optimal dose for Prevention of Malaria in Young Caucasian Children. Br J Clin Pharmacol 2019; 85:100-13.
[65] Singhasivanon V, Chongsuphajaisiddhi T, Sabcharoen A, Attanath P, Webster H, Wernsdorfer W, et al. Pharmacokinetics of Mefloquine in Children Aged 6 to 24 Months. Eur J Drug Metab Pharmacokinet 1992;17:275-9.
[66] Food and Drug Administration. FDA Package Insert of Mefloquine (Lariam). Silver Spring: Food and Drug Administration.
[67] Heimbach T, Lin W, Hourcade-Potelleret F, Tian X, Combes FP, Horvath N, et al. Physiologically based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients. J Pharm Sci 2019;108:2191-8.
[68] Food and Drug Administration. FDA Package Insert of Nilotinib (TASIGNA). Silver Spring: Food and Drug Administration; 2010.
[69] Johnson TN, Abduljalil K, Nicolas J, Muglia P, Chanteux H, Nicolai J, et al. Use of a Physiologically Based Pharmacokinetic-Pharmacodynamic Model for Initial dose Prediction and Escalation during a Paediatric Clinical Trial. Br J Clin Pharmacol 2020;87:1378-89.
[70] Bunglawala F, Rajoli RK, Mirochnick M, Owen A, Siccardi M. Prediction of Dolutegravir Pharmacokinetics and dose Optimization in Neonates Via Physiologically Based Pharmacokinetic (PBPK) Modelling. J Antimicrob Chemother 2020;75:640-7.
[71] Food and Drug Administration. FDA Package Insert of Dolutegravir (TIVICAY). Silver Spring: Food and Drug Administration; 2013.
[72] Zheng L, Xu M, Tang SW, Song HX, Jian XH, Wang L. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization. Pharm Res 2019;36:171-83.
[73] Olkkola KT, Hamunen K, Seppala T, Maunuksela E. Pharmacokinetics and Ventilatory Effects of Intravenous Oxycodone in Postoperative Children. Br J Clin Pharmacol 1994;38:71-6.
[74] Poyhia R, Olkkola KT, Seppala T, Kalso E. The Pharmacokinetics of Oxycodone after Intravenous Injection in Adults. Br J Clin Pharmacol 1991;32:516-8.
[75] Kokki M, Heikkinen M, Valitalo P, Hautajarvi H, Hokkanen J, Pitkänen H, et al. Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: Oxycodone and its Metabolites in Plasma and Urine. Br J Clin Pharmacol 2017;83:791-800.
[76] Maharaj AR, Barrett JS, Edginton AN. A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam. AAPS J 2013;15:455-64.
[77] Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan P, et al. Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients with and without Status Epilepticus. J Pediatr 2012;160:667-72.
[78] McDermott CA, Kowalczyk AL, Schnitzler ER, Mangurten HH, Rodvold KA, Metrick S. Pharmacokinetics of Lorazepam in Critically Ill Neonates with Seizures. J Pediatr 1992;120:479-83.
[79] Food and Drug Administration. FDA Package Insert of Lorazepam (Ativan injection). Silver Spring: Food and Drug Administration.
[80] Rashid M, Sarfraz M, Arafat M, Hussain A, Abbas N, Sadiq MW, et al. Prediction of Lisinopril Pediatric dose from the Reference Adult Dose by Employing a Physiologically Based Pharmacokinetic Model. BMC Pharmacol Toxicol 2020;21:56.
[81] McLean AJ, Drummer OH, Smith HJ, Froomes P, McNeil JJ. Comparative Pharmacokinetics of Enalapril and Lisinopril, alone and with Hydralazine. J Hum Hypertens 1989;3:147-51.
[82] Shaw W, Hogg R, Delucchi A, Sakihara G, Wells T, Tenney F, et al. Lisinopril (L) Pharmacokinetics (PK) in Hypertensive Children and Infants. Am J Hypertens 2002;15:46A.
[83] Mansoor N, Ahmad T, Alam Khan R, Sharib SM, Mahmood I. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. Am J Ther 2019;26:e32-7.
[84] Schwagmeier R, Alincic S, Striebel HW. Midazolam Pharmacokinetics following Intravenous and Buccal Administration. Br J Clin Pharmacol 1998;46:203-6.
[85] Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of Midazolam in Critically Ill Neonates. Eur J Clin Pharmacol 1990;39:191-2.
[86] Lutz JD, Mathias A, German P, Pikora C, Reddy S, Kirby BJ. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and its Metabolites to Support dose Selection for the Treatment of Pediatric Patients with COVID-19. Clin Pharmacol Ther 2021;109:1116-24.
[87] Maharaj AR, Wu H, Hornik CP, Balevic SJ, Hornik CD, Smith PB, et al. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients with Coronavirus Disease 2019. JAMA Pediatr 2020;174:e202422.
[88] Mahmood I, Tegenge MA. A Comparative Study between Allometric Scaling and Physiologically based Pharmacokinetic Modeling for the Prediction of Drug Clearance from Neonates to Adolescents. J Clin Pharmacol 2019;59:189-97.
[89] Mahmood I. Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models. J Clin Pharmacol 2016;56:733-9.
[90] Mahmood I. Prediction of Clearance, Volume of Distribution, and Half-Life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach. Eur J Drug Metab Pharmacokinet 2017;42:601-10.
[91] Mahmood I, Staschen CM. Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models. AAPS J 2016;18:445-54.
[92] Mahmood I, Ahmad T, Mansoor N, Sharib SM. Prediction of Clearance in Neonates and Infants (≤3 Months of Age) for Drugs which are Glucuronidated: A Comparative Study between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. J Clin Pharmacol 2017;57:476-83.
[93] Calvier EA, Krekels EH, Välitalo PA, RostamiHodjegan A, Tibboel D, Danhof M, et al. Allometric Scaling of Clearance in Paediatric Patients: When does the Magic of 0.75 Fade? Clin Pharmacokinet 2017;56:273-85.
[94] Mahmood I. Misconceptions and Issues Regarding Allometric Scaling During the Drug Development Process. Expert Opin Drug Metab Toxicol 2018;14:843-54.
[95] Mahmood I, Tegenge MA. Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. J Clin Pharmacol 2021;61:S108-16.
[96] Mahmood I. Prediction of Clearance in Children from Adults Following Drug-Drug Interaction Studies: Application of Age-Dependent Exponent Model. Drugs R D 2020;20:47-54.
[97] Björkman S. Prediction of Drug Disposition in Infants and Children by Means of Physiologically Based Pharmacokinetic (PBPK) Modelling: Theophylline and Midazolam as Model Drugs. Br J Clin Pharmacol 2004;59:691-704.
[98] Björkman S. Reduction and Lumping of Physiologically based Pharmacokinetic Models: Prediction of the Disposition of Fentanyl and Pethidine in Humans by Successively Simplified Models. J Pharmacokinet Pharmacodyn 2003;30:285-307.
[99] Cao Y, Jusko WJ. Applications of Minimal Physiologically based Pharmacokinetic Models. J Pharmacokinet Pharmacodyn 2012;39:711-23.
[100] Cao Y, Balthasar JP, Jusko WJ. Second-Generation Minimal Physiologically-Based Pharmacokinetic Model for Monoclonal Antibodies. J Pharmacokinet Pharmacodyn 2013;40:597-609.
[101] Thémans P, Marquet P, Winkin JJ, Musuamba FT. Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia. Drugs R D 2019;19:177-89.
[102] Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative Pharmacokinetics of Coumarin Anticoagulants L: Physiologic Modeling of S-Warfarin in Rats and Pharmacologic Target-Mediated Warfarin Disposition in Man. J Pharm Sci 2003;92:985-94.
[103] Mahmood I. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model. Drugs R D 2020;20:377-87.
[104] Johnson TN, Ke AB. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where do we Draw the Line? J Clin Pharmacol 2021;61:S83-93.
[105] Box GE. Science and Statistics. J Am Stat Assoc 1976;71:791-99.
[106] Deyme L, Benzekry S, Ciccolini J. Mechanistic Models for Hematological Toxicities: Small is Beautiful. CPT Pharmacometrics Syst Pharmacol 2021;10:396-98.